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Background: Enzyme prodrug therapy shows promise for the treatment of solid tumors, but current approaches
lack effective/safe delivery strategies. To address this, we previously developed three enzyme-containing fusion
proteins targeted via annexin V to phosphatidylserine exposed on the tumor vasculature and tumor cells, using the
enzymes L-methioninase, purine nucleoside phosphorylase, or cytosine deaminase. In enzyme prodrug therapy, the
fusion protein is allowed to bind to the tumor before a nontoxic drug precursor, a prodrug, is introduced. Upon
interaction of the prodrug with the bound enzyme, an anticancer compound is formed, but only in the direct
vicinity of the tumor, thereby mitigating the risk of side effects while creating high intratumoral drug concentrations.
The applicability of these enzyme prodrug systems to treating prostate cancer has remained unexplored. Additionally,
target availability may increase with the addition of low dose docetaxel treatment to the enzyme prodrug treatment,
but this effect has not been previously investigated. To this end, we examined the binding strength and the cytotoxic
efficacy (with and without docetaxel treatment) of these enzyme prodrug systems on the human prostate cancer cell
line PC-3.
Results: All three fusion proteins exhibited strong binding; dissociation constants were 0.572 nM for
L-methioninase-annexin V (MT-AV), 0.406 nM for purine nucleoside phosphorylase-annexin V (PNP-AV), and
0.061 nM for cytosine deaminase-annexin V (CD-AV). MT-AV produced up to 99% cell death (p < 0.001) with
limited cytotoxicity of the prodrug alone. PNP-AV with docetaxel created up to 78% cell death (p < 0.001) with
no cytotoxicity of the prodrug alone. CD-AV with docetaxel displayed up to 60% cell death (p < 0.001) with no
cytotoxicity of the prodrug alone. Docetaxel treatment created significant increases in cytotoxicity for PNP-AV
and CD-AV.
Conclusions: Strong binding of fusion proteins to the prostate cancer cells and effective cell killing suggest
that the enzyme prodrug systems with MT-AV and PNP-AV may be effective treatment options. Additionally,
low-dose docetaxel treatment was found to increase the cytotoxic effect of the annexin V-targeted therapeutics
for the PNP-AV and CD-AV systems.
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Prostate cancer (PC) is the most common non-skin malig-
nancy and the second leading cause of cancer-related
death in American men [1], yet remains essentially incur-
able. Since the introduction of PSA specific screening, the
lethality of prostate cancer stems not from a lack of early
detection but more commonly from the failure of loco-
regional therapies creating a need for improved systemic
therapies [2]. Currently, most single-agent anticancer
drugs face challenges due to increased multidrug resist-
ance [3], pharmacokinetic limitations [4,5], and restricted
clinical dosage or frequency of administration due to cyto-
toxicity in non-cancerous tissues [6-8].
Antibody-directed enzyme prodrug therapy (ADEPT),
gene-directed enzyme prodrug therapy (GDEPT), and
viral-directed enzyme prodrug therapy (VDEPT) have
been investigated as means to utilize enzymes to convert
relatively non-toxic prodrugs into clinically relevant con-
centrations of cytotoxic drugs directly at tumor sites.
However, all three of these approaches have significant
limitations [9-11]. To improve upon the clinical applicabil-
ity, efficacy, and safety of enzyme prodrug therapy, we pre-
viously developed three fusion proteins (FPs), each
targeted to primary tumors, their metastases, and the
tumor vasculature. This dual targeting strategy allows for
two distinct mechanisms of killing: (i) via the direct action
of the cytotoxic drug on the tumor cells, and (ii) by killing
tumor vasculature endothelial cells and thereby effectively
cutting off the tumor blood supply. Vascular targeting
makes these FPs an attractive option because endothelial
cells are relatively genetically-stable, easily-accessible tar-
gets that enable therapeutic effect amplification through
tumor infarction, as well as tumor-type independent tar-
geting [12]. PC is especially well suited to this dual target-
ing strategy as prostate carcinomas have been shown to
have approximately twice the vascular density of healthy
prostate tissue [13] and microvessel density serves as a
predictor of cancer-specific survival [14]. To date, the effi-
cacy of these targeted enzyme prodrug systems on PC has
remained unexplored.
Human annexin V (AV) is used to target each FP. AV
has a strong affinity to the anionic phospholipid phospha-
tidylserine (PS), normally tightly segregated to the inner
leaflet in eukaryotic plasma membranes [15], but robustly
and consistently expressed on the outer leaflet in a wide
range of cancer cell lines, their metastases [16,17], and the
luminal side of tumor endothelium [18,19]. To maximize
FP binding to tumor cells, we investigated treatment with
docetaxel, a tubulin/microtubule targeting chemotherapeu-
tic agent [20], which is becoming increasingly important in
combination therapies for metastatic, hormone-refractory
PC [21]. Therapeutic docetaxel dosage is limited by drug
toxicity [7] but a single subtoxic dose has been shown to in-
crease PS exposure on tumor endothelium by ~70%without causing apoptosis or changing PS exposure on nor-
mal endothelium [22]. This large increase in AV binding
sites has the potential to increase the cytotoxic power of
our enzyme prodrug systems.
We previously developed three AV-targeted FPs, each
containing a non-human enzyme [23-25]. The enzymes
utilized are:
(i) L-methioninase (MT), which converts
L-selenomethionine (SeMet) to toxic methylselenol,
α-ketobutyrate, and ammonia [26]. MT also converts
the amino acid methionine to methanethiol, which
provides a second point of attack since most cancer
cells exhibit increased methionine-dependence
[27,28]. PC cell lines have shown sensitivity to
non-targeted MT/SeMet treatment in vitro [29].
(ii) Purine nucleoside phosphorylase (PNP), which
converts fludarabine (FD) into highly cytotoxic
2-fluoroadenine (2-FA) that incorporates into
DNA/RNA, thereby effectively killing both dividing
and nondividing cells [30]. PNP exhibits a powerful
bystander effect [31,32], and PC cells have shown
sensitivity to PNP/FD GDEPT treatment [33-35].
(iii) Cytosine deaminase (CD), which converts the
nucleoside analog 5-fluorocytosine (5-FC) to the
more toxic pyrimidine analog 5-fluorouracil (5-FU),
metabolites of which misincorporate into DNA/
RNA and inhibit the nucleotide synthesis enzyme
thymidylate synthetase [36]. PC cell lines have
shown sensitivity to 5-FU and GDEPT CD/5-FC
treatment [37].
To address the vascular targeting capabilities of these
enzyme prodrug systems, we have previously shown that
all three FPs bind tightly to PS expressing human abdom-
inal aorta endothelial cells (HAAE-1) in vitro, with dissoci-
ation constants ranging from 0.5-1.5 nM [23-25].
Cytotoxic efficacy of our FP systems on HAAE-1 cells has
also been demonstrated previously in vitro, with cell kill-
ing ranging from 5-100% [23-25]. We have validated these
in vitro methods for determining vascular targeting/cyto-
toxic efficacy via the successful transition of the MT-AV/
SeMet system in vivo for mice with implanted MDA-MB-
231 breast tumors [38].
In the present study, we characterize the binding and
evaluate the in vitro anticancer efficacy of three enzyme
prodrug systems on PC-3 human prostate carcinoma
cells in the presence and absence of low-dose docetaxel
treatment.
Methods
Expression and purification of fusion proteins
All FPs were expressed and purified as described previ-
ously [23-25]. Briefly, polymerase chain reaction (PCR)
Guillen et al. Journal of Biomedical Science 2014, 21:65 Page 3 of 8
http://www.jbiomedsci.com/content/21/1/65was used amplify genes encoding each enzyme, a six resi-
due flexible linker, annexin V, an N- or C- terminal His6
tag, and an engineered HRV 3C protease cleavage site.
Plasmids containing each FP were created via transform-
ation of NovaBlue competent cells and then expressed in
E.coli BL21 (DE3) cells. Recombinant FPs were produced
and purified according to the procedure of Zang et al. [39]
using immobilized metal (Ni2+) affinity chromatography.
The His6 tag was removed during purification by cleavage
with HRV-3C protease (Merck, Darmstadt, Germany). FPs
were lyophilized and stored at −80°C.
Cell culture
The PC-3 human prostate adenocarcinoma cell line was
obtained from the American Type Culture Collection
(ATTC, Manassas, VA, USA) and cultured in F-12 K
medium (ATTC) supplemented with 10% fetal bovine
serum, 100 U/ml penicillin, and 100 μg/ml streptomycin
(all from Atlanta Biologics, Flowery Branch, GA, USA)
at 37°C in a 5% CO2 atmosphere. Cells were passaged at
70-80% confluence, 2–3 times per week, less than 12
times during the course of experiments.
In vitro binding assays
Cells were grown in T-75 flasks to 70-80% confluence,
plated at 50 k cells/well in 24-well cell culture plates, and
allowed to grow to 90% confluence. Dissociation constants
were determined as described previously [23-25]. Briefly,
cells were fixed with 0.25% glutaraldehyde in PBS, then
quenched with 50 nM NH4Cl in PBS. After a 1 h of incu-
bation with 0.5% BSA in PBS, cells were washed, and vary-
ing concentrations (0–20 nM) of SureLINK biotin (KPL,
Gaithersburg, MD, USA) labeled FPs were added and
allowed to bind at 37°C for 2 h. Cells were washed with
PBS containing 0.5% BSA and treated with streptavidin-
horseradish peroxidase (2 μg/ml, KPL) for 1 h at room
temperature. Cells were washed, and HRP was quantified
via chromogenic substrate o-phenylenediamine (0.4 mg/ml)
in 0.05 mM phosphate–citrate buffer (pH 5.0) containing
0.012% hydrogen peroxide. Since Ca2+ is essential for AV
binding to PS, the above procedure was conducted in the
presence of 2 mM Ca2+ (total binding) and in the absence
of Ca2+ with 5 mM EDTA to chelate any residual Ca2+
(non-specific binding). All experiments contained a blank
subjected to the same procedure but with 0 nM FP.
In vitro enzyme prodrug cytotoxic efficacy
Studies were carried out over a 6-day (MT-AV, PNP-AV)
or 9-day (CD-AV) treatment cycle. Cells were plated as
described previously, but only allowed to reach 50-60%
confluence. Prior to the first viability assay, selected wells
were pre-treated with 50 pM docetaxel (Biotang, Waltham,
MA, USA). All medium was enhanced with 2 mM Ca2+
since annexin V binding is calcium-dependent. Medium forMT-AV cytotoxicity studies was also supplemented with
0.02 mM pyridoxal phosphate (co-factor). Cells were
treated with a saturating concentration of FP (100 nM)
every 3 days for 2 h at 37°C in accordance with previous
binding stability studies [23-25]. Each day, medium was re-
placed with medium containing varying concentrations of
prodrug (L-SeMet and 5-FC from Fisher Scientific, Wal-
tham, MA, USA and FD from VWR, Radnor, PA, USA) or
drug analog (2-FA from Fisher Scientific and 5-FU from
Sigma-Aldrich, St. Louis, MO, USA) with or without 50
pM docetaxel. This docetaxel concentration was chosen
since it is similar to the level previously reported to lead to
PS exposure in vitro without a cytotoxic effect on cells [22].
An Alamar Blue (Invitrogen, Grand Island, NY, USA) assay
was preformed every 2–3 days to measure cell viability
[40]. Cells were incubated with 10% Alamar Blue in fresh
media for 4 h at 37°C. From each well, 250 μl was trans-
ferred to an opaque 96-well plate, and fluorescence (530/
590 nm) was read on a microtiter plate reader. Cells were
washed twice after each Alamar Blue assay and three times
after each FP incubation before prodrug/drug treatments
were added.
Data analysis
All treatments were run in triplicate. Dissociation con-
stants were obtained using Prism 5 software (GraphPad,
La Jolla, CA, USA). Statistical significance was determined
with Prism 5 via a one-way ANOVA employing the
Tukey-Kramer multiple comparisons test.
Results
Binding strength
The ability of each FP to bind to PS on the PC-3 cell sur-
face was determined by measuring the total binding and
non-specific binding and subtracting to obtain specific
binding, with typical results shown in Figure 1 for MT-
AV. The dissociation constant (Kd) was calculated utilizing
a one-site, non-competitive binding model, and Kd values
are presented in Table 1.
Enzyme prodrug cytotoxic efficacy
We evaluated the cytotoxic effect of each enzyme prodrug
therapy on PC-3 cells by comparing the cell viability on
days 2, 4, and 6 (MT-AV and PNP-AV) or days 3, 6, and 9
(CD-AV) to day 0 on a per well basis, and results are pre-
sented as percent viability compared to day 0. Statistical sig-
nificance was established by comparing cells treated with
varying concentrations of prodrug (or drug analog, if avail-
able) to their corresponding control groups treated with
0 μM drug/prodrug on the same day (#, p < 0.05; *, p < 0.01;
and **, p < 0.001). Additionally, cells treated with 50 pm do-
cetaxel were compared to cells not treated with docetaxel
at the same concentrations of prodrug/drug on the same
day (^, p < 0.05; +, p < 0.01; and ++, p < 0.001).
Figure 1 Binding strength of MT-AV to PC-3 cell surface PS.
PC-3 cells were incubated with increasing concentrations of biotin
labeled MT-AV with total binding (●) measured in the presence of
2 mM Ca2+ and non-specific binding (■) measured in the absence of
Ca2+ with 5 mM EDTA to chelate any residual Ca2+. Specific binding
(▲) was obtained by subtracting non-specific from total binding.
Data presented as mean ± SE (n = 3).
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was evaluated over 6 days with SeMet concentrations
ranging from 0 to 1000 μM with 50 pM docetaxel (data
not shown) and without docetaxel (Figure 2). MT-AV/
SeMet treatment caused significant cytotoxicity starting
at 250 μM SeMet, resulting in 64% viability by day 2 and
14% viability by day 6, with no growth inhibition for SeMet
alone. At SeMet concentrations above 250 μM, MT-AV/
SeMet killing velocity increased and near complete killing
was achieved by day 6, with only slight growth inhibitory ef-
fects of SeMet alone. The addition of docetaxel treatment
created no significant additional decreases in cell viability.
The cytotoxic effect of 2-FA converted from FD by
PNP-AV in the presence (Figure 3(a)) and absence (see
Additional file 1: Figure S1) of docetaxel treatment was
determined over 6 days with FD or 2-FA concentrations
ranging from 0 to 10 μM. PNP-AV in combination with
5 μM FD was the lowest concentration of prodrug that
showed significant cytotoxic effects, reaching 37% viability
by day 6 with docetaxel treatment and 50% viability with-
out docetaxel treatment. Cytotoxicity effects increased
with increasing FD concentration up to 10 μM, reaching
22% viability by day 6 with docetaxel treatment and 37%
viability without docetaxel treatment. Treatment withTable 1 Dissociation constant (Kd) of each fusion protein
binding to PC-3 cells
Fusion protein Kd ± SE (nM)
MT-AV 0.572 ± 0.281
PNP-AV 0.406 ± 0.108
CD-AV 0.061 ± 0.026PNP-AV/FD was statistically indistinguishable from 2-FA
treatment alone at concentrations ≥ 5 μM for docetaxel
treated cells, but for non-docetaxel treated cells this treat-
ment similarity did not occur at the concentrations evalu-
ated (see Additional file 1: Figure S1). FD treatment alone
did not show any cytotoxic effects at concentrations ≤
10 μM. Treatment only with docetaxel did not affect PC-3
cells, but the addition of docetaxel significantly enhanced
PNP-AV/FD cytotoxic efficacy at 5 μM FD concentrations
and above as indicated (^, +, ++) in Figure 3(a). Additional
decreases in % cell viability that occurred with docetaxel
treatment are presented in Figure 3(b) for FD concentra-
tions of 5, 7.5, and 10 μM. On day 2, additional decreases
in % cell viability ranged from 15-19%. The highest add-
itional cytotoxicity occurred on day 4 (22-27%), and the ef-
fect diminished by day 6.
The cytotoxic effect of 5-FU converted from 5-FC by
CD-AV with (Figure 4(a)) and without (see Additional
file 1: Figure S2) docetaxel treatment was evaluated over
9 days with concentrations of 5-FC/5-FU ranging from 0
to 5000 μM. CD-AV/5-FC treatment caused significant
cytotoxicity at all concentrations above 500 μM but was
most effective at 5000 μM 5-FC resulting in 40% viability
by day 9 with docetaxel treatment and 44% without do-
cetaxel treatment. No significant increases in cytotox-
icity occurred past 5000 μM CD-AV/5-FC or 5-FU
treatment (data not shown). 5-FC treatment alone exhib-
ited no cytotoxic effect for both docetaxel and non-
docetaxel treated cells. Treatment with the drug analog
5-FU showed significantly more cytotoxic effects than
treatment with CD-AV/5-FC from day 6 onwards and
resulted in ~6% viability for both docetaxel and non/do-
cetaxel groups. Treatment only with docetaxel had no
effect on PC-3 cells, but the addition of docetaxel signifi-
cantly affected the killing efficacy of the CD-AV/5-FC
system as indicated in Figure 4(a) (^, +). The additional
decreases in % viability as a result of docetaxel addition
are presented in Figure 4(b). Docetaxel affected CD-AV/
5-FC efficacy in an inverse dose dependent manner, with
respect to the prodrug, as the largest additional de-
creases in % viability consistently occurred at 1000 μM
5-FC and the smallest additional decreases were consist-
ently seen at 5000 μM 5-FC. As for PNP-AV/FD, the im-
pact of docetaxel was greatest in the middle of the study
reaching an additional decrease in % viability of 26% on
Day 6 for 1000 μM 5-FC.
Discussion
The MT-AV/SeMet enzyme prodrug system emerged as
a promising treatment option as it displayed significant
cytotoxicity in vitro at feasible in vivo SeMet treatment
concentrations. The median lethal dose (LD50) of SeMet
in vivo for female nude mice is 12.5 mg/kg [41,42],
which translates to ~1100 μM in vitro. A high degree of
Figure 2 Effect of SeMet conversion by MT-AV on PC-3 cell viability. Cells treated with varying concentrations of SeMet were compared
their corresponding control groups treated with 0 nM concentrations on the same day, and significant differences are denoted by # (p < 0.05),
* (p < 0.01), and ** (p < 0.001). Data presented as mean ± SE (n = 3).
Figure 3 Effect of FD conversion by PNP-AV with 50 pM docetaxel on PC-3 cell viability. (a) Cells treated with varying concentrations of
FD or 2-FA were compared to their corresponding control groups treated with 0 nM concentrations on the same day, and significant differences
are denoted by # (p < 0.05), * (p < 0.01), and ** (p < < 0.001). Cells treated with 50 pm docetaxel (shown) were compared to cells not treated with
docetaxel (see Additional file 1: Figure S1) at the same concentrations of FD or 2-FA on the same day, and significant differences are denoted by
^ (p < 0.05), + (p < 0.01), and ++ (p < 0.001). Data presented as mean ± SE (n = 3). (b) Additional decreases in cell viability afforded by the addition
of 50 pM docetaxel to the PNP-AV system efficacy, shown for prodrug titers for which docetaxel treatment influenced treatment outcome. Results
shown as non-docetaxel treated % viability minus docetaxel treated % viability to obtain a measure of additional cell killing with docetaxel
treatment that alone has no significant effect on cell growth. Data presented as mean ± SE (n = 6).
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Figure 4 Effect of CD-AV conversion of 5-FC with 50 pM docetaxel treatment on PC-3 cell viability. (a) Cells treated with varying
concentrations of 5-FC or 5-FU were compared their corresponding control groups treated with 0 nM concentrations on the same day, and
significant differences are denoted by # (p < 0.05), * (p < 0.01), and ** (p < 0.001). Cells treated with 50 pm docetaxel were compared to cells not
treated with docetaxel (see Additional file 1: Figure S2) at the same concentrations of 5-FC or 5-FU on the same day and significant differences
are denoted by ^ (p < 0.05) or + (p < 0.01). Data presented as mean ± SE (n = 3). (b) Additional decreases in cell viability by the addition of 50 pM
docetaxel, which alone has no effect on cell viability, for prodrug concentrations where docetaxel additional affected treatment outcomes. Results
shown as non-docetaxel treated % viability minus docetaxel treated % viability to obtain a measure of additional cell killing with docetaxel
treatment that alone has no significant effect on cell growth. Data presented as mean ± SE (n = 6).
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concentrations as low as 250 μM with minimal cytotox-
icity of SeMet alone, suggesting a feasible window of op-
portunity for in vivo treatment translation.
PNP-AV also emerged as a feasible option for treating
PC as it displayed high killing velocity and killing efficacy,
both of which are important for clinical translation. PNP-
AV also showed the most robust increase in cell killing ef-
ficacy in the presence of docetaxel. PNP-AV/FD (with do-
cetaxel) created up to 78% cytotoxicity over 6 days at an
FD concentration of 10 μM in vitro, which translates to
less than 0.1% of the LD50 (~1200 mg/kg) for FD in female
nude mice, indicating that this therapy could be adminis-
tered with minimal harm to healthy tissues.
CD-AV/5-FC treatment was not as effective or as rapid
as MT-AV/SeMet or PNP-AV/FD treatment, and wetherefore conclude that CD-AV/5-FC would most likely
not be effective in vivo. Additionally, the prodrug concen-
tration necessary to elicit a cytotoxic effect was signifi-
cantly higher than for the MT-AV and PNP-AV systems,
although even at the highest level of prodrug, there was
no effect of the prodrug by itself.
All three FPs exhibited relatively strong binding to PS
on PC-3 cells with dissociation constants less than previ-
ously reported dissociation constants for AV alone to PS
(2.7–15.5 nM) [43,44]. The multimeric structure of each
FP likely allows for multiple AV to PS bonds per FP, and
we believe this contributes to the observed strong bind-
ing of FPs to PS.
Subtoxic docetaxel treatment significantly but selectively
increased the cytotoxic efficacy of our enzyme prodrug
systems, suggesting that at least two of our FP/prodrug
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exposure. Tumor xenografts in murine models expose ~
35% of PS on the external leaflet [18] (with > 106 PS mole-
cules per cell [22]), but docetaxel treatment can increase
PS expose and thereby the number of potential FP binging
sites by up to 70% [22], effectively doubling the FP targets
and thereby creating quicker and more powerful treat-
ment. The additional decrease in cell viability caused by
introducing docetaxel to the PNP-AV and CD-AV enzyme
prodrug treatments is seen in Figures 3(b) and 4(b), re-
spectively. The maximum effect was present at about the
midpoint of each study, i.e. at day 4 in the PNP-AV system
and at day 6 in the CD-AV system. We believe that the
peak in this effect is a result of increased initial prodrug to
drug turnover enabled by the increased presence of bound
FP’s due to the additional availability of PS binding sites.
Therefore, the addition of docetaxel causes the enzyme
prodrug treatment to speed up initially; and later as the
number of viable cells dwindles, the effect becomes rela-
tively less noticeable.
We employed subtoxic treatment levels of docetaxel,
as we were interested in the PS exposure effects of doce-
taxel and not its cytotoxic capabilities. Not only did do-
cetaxel treatment alone have no growth inhibitory or
cytotoxic effects, but the addition of docetaxel treatment
did not alter the cytotoxic efficacy of the drug analogs,
2-FA and 5-FU. This indicates there was no synergism
present between the drugs generated by our enzyme
prodrug therapies and docetaxel. Therefore, it is prob-
able that the increased cytotoxic effect afforded by doce-
taxel treatment was in fact due to an increase in PS
exposure providing an increase in available binding sites
for our FPs.
Unexpectedly, docetaxel treatment did not increase MT-
AV cytotoxicity on PC-3 cells. We propose that this effect
did not occur because the killing efficacy of the MT-AV sys-
tem may already be saturated at feasible SeMet concentra-
tions without docetaxel. Saturation could arise if the
amount of MT-AV able to bind without docetaxel treat-
ment is sufficient to convert the available SeMet, as any
additional MT-AV binding would increase the initial SeMet
turnover rate but would not ultimately affect the quantity
of reactive oxygen species the cells are exposed to.
Further validation of the MT-AV and PNP-AV systems
will consist of in vivo work in murine xenograft models.
The immunogenicity of the FP systems can be addressed
via functionalization of human homologs [45,46] or via
PEGylation [47].
Conclusions
In conclusion, we have substantiated the feasibility of
two, novel, non-invasive treatments for prostate cancer
and its metastases with minimal threat to healthy tissues.
We were able to achieve both tight binding, withdissociation constants in the low nanomolar range, and
excellent cytotoxic efficacy for the MT-AV and PNP-AV
enzyme prodrug systems. Additionally we have shown
the utility of subtoxic docetaxel treatment for increasing
the cytotoxic potential of annexin V-targeted enzyme
prodrug systems.
Additional file
Additional file 1: Figure S1. Effect of FD conversion by PNP-AV on
PC-3 cell viability. Figure S2. Effect of 5-FC conversion by CD-AV on PC-3
cell viability.
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